Chiron makes third-quarter loss despite higher diagnostics sales
This article was originally published in Clinica
Executive Summary
US biotechnology company Chiron's acquisition of gene therapy company Viagene resulted in a third-quarter loss of $145 million due to one-time charges of $149 million.